MORPHINAN-DERIVATIVES FOR TREATING DIABETES AND RELATED DISORDERS
    2.
    发明公开

    公开(公告)号:EP2747754A1

    公开(公告)日:2014-07-02

    申请号:EP12756653.7

    申请日:2012-08-22

    CPC分类号: A61K31/485 A61K31/155

    摘要: The invention relates to a morphinan-derivative that targets NMDA receptors on pancreatic islets and has the general formula (I) wherein R
    1 is selected from -OH, -CO
    2 H, -R
    0 , -OR
    0 , -OC(=O)R
    0 , -OC(=O)OR
    0 or -OC(=O)NHR
    0 ; and R
    2 is selected from -H, -R
    0 , -C(=O)R
    0 , -C(=O)OR
    0 , -C(=O)NHR
    0 or -C(=NH)-NH- C(=NH)-NH
    2 ; wherein R
    0 is in each case independently selected from -C
    1 -C
    6 -alkyl, - aryl, -heteroaryl, -C
    1 -C
    6 -alkyl-aryl or -C
    1 -C
    6 -alkyl-heteroaryl, in each case independently unsubstituted or substituted; or its physiologically acceptable salt and/or stereoisomer, including mixtures thereof in all ratios, for use in the treatment of a disease or condition, where the disease or condition is insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, and/or diabetic nephropathy.

    摘要翻译: 本发明涉及靶向胰岛上的NMDA受体的吗啡喃衍生物,具有通式(I),其中R 1选自-OH,-CO 2 H,-R 0,-OR 0,-OC(= O)R 0,-OC (= O)OR0或-OC(= O)NHR0; 并且R 2选自-H,-R 0,-C(= O)R 0,-C(= O)OR 0,-C(= O)NHR 0或-C(= NH)-NH-C(= NH2; 其中R 0在每种情况下独立地选自-C 1 -C 6 - 烷基, - 芳基, - 杂芳基,-C 1 -C 6 - 烷基 - 芳基或-C 1 -C 6 - 烷基 - 杂芳基,在每种情况下独立地为未取代或取代的; 或其生理上可接受的盐和/或立体异构体,包括其所有比例的混合物,用于治疗疾病或病症,其中疾病或病症是胰岛素依赖性糖尿病,非胰岛素依赖性糖尿病,肥胖症, 和/或糖尿病性肾病。